WallStSmart

Empro Group Inc. Ordinary shares (EMPG)vsHenry Schein Inc (HSIC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Henry Schein Inc generates 240278% more annual revenue ($13.18B vs $5.48M). EMPG leads profitability with a 13.7% profit margin vs 3.0%. HSIC trades at a lower P/E of 22.6x. HSIC earns a higher WallStSmart Score of 56/100 (C).

EMPG

Hold

47

out of 100

Grade: D+

Growth: 5.3Profit: 9.0Value: 3.0Quality: 8.5
Piotroski: 6/9Altman Z: 3.11

HSIC

Buy

56

out of 100

Grade: C

Growth: 7.3Profit: 5.5Value: 8.7Quality: 7.0
Piotroski: 5/9Altman Z: 2.71
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

EMPGSignificantly Overvalued (-2745.9%)

Margin of Safety

-2745.9%

Fair Value

$0.61

Current Price

$17.36

$16.75 premium

UndervaluedFair: $0.61Overvalued
HSICUndervalued (+12.5%)

Margin of Safety

+12.5%

Fair Value

$93.39

Current Price

$74.25

$19.14 discount

UndervaluedFair: $93.39Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

EMPG4 strengths · Avg: 10.0/10
Return on EquityProfitability
66.3%10/10

Every $100 of equity generates 66 in profit

Operating MarginProfitability
36.1%10/10

Strong operational efficiency at 36.1%

Revenue GrowthGrowth
141.6%10/10

Revenue surging 141.6% year-over-year

Altman Z-ScoreHealth
3.1110/10

Safe zone — low bankruptcy risk

HSIC1 strengths · Avg: 8.0/10
Price/BookValuation
2.6x8/10

Reasonable price relative to book value

Areas to Watch

EMPG4 concerns · Avg: 3.3/10
Price/BookValuation
17.0x4/10

Trading at 17.0x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$143.05M3/10

Smaller company, higher risk/reward

P/E RatioValuation
192.9x2/10

Premium valuation, high expectations priced in

HSIC3 concerns · Avg: 3.3/10
PEG RatioValuation
1.604/10

Expensive relative to growth rate

Profit MarginProfitability
3.0%3/10

3.0% margin — thin

Debt/EquityHealth
1.023/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : EMPG

The strongest argument for EMPG centers on Return on Equity, Operating Margin, Revenue Growth. Revenue growth of 141.6% demonstrates continued momentum.

Bull Case : HSIC

The strongest argument for HSIC centers on Price/Book.

Bear Case : EMPG

The primary concerns for EMPG are Price/Book, EPS Growth, Market Cap. A P/E of 192.9x leaves little room for execution misses.

Bear Case : HSIC

The primary concerns for HSIC are PEG Ratio, Profit Margin, Debt/Equity. Thin 3.0% margins leave little buffer for downturns.

Key Dynamics to Monitor

EMPG profiles as a growth stock while HSIC is a value play — different risk/reward profiles.

EMPG is growing revenue faster at 141.6% — sustainability is the question.

HSIC generates stronger free cash flow (338M), providing more financial flexibility.

Monitor MEDICAL DISTRIBUTION industry trends, competitive dynamics, and regulatory changes.

Bottom Line

HSIC scores higher overall (56/100 vs 47/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Empro Group Inc. Ordinary shares

HEALTHCARE · MEDICAL DISTRIBUTION · USA

Empro Group Inc., through its subsidiary, sells healthcare and beauty products in Malaysia and internationally. The company is headquartered in Shah Alam, Malaysia.

Visit Website →

Henry Schein Inc

HEALTHCARE · MEDICAL DISTRIBUTION · USA

Henry Schein, Inc. is an American distributor of health care products and services with a presence in 32 countries.

Visit Website →

Want to dig deeper into these stocks?